Fentanyl-Rewired: A 2‑Azaspiro[3.3]heptane Core Preserves μ‑Opioid Function.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Neuroscience

Background:

• Fentanyl is a potent μ-opioid receptor (MOR) agonist used for pain relief.
• A major limitation of fentanyl is its significant respiratory depressant effects.
• Developing novel analgesics with reduced respiratory liability is a critical unmet medical need.

Purpose of the Study:

• To investigate the impact of replacing the piperidine moiety in fentanyl with a 2-azaspiro[3.3]-heptane group.
• To assess the pharmacological profile, including receptor binding, signaling, and antinociceptive effects, of the novel spiro analogue.
• To evaluate the respiratory effects and pharmacokinetic properties of the spiro analogue in vivo.

Main Methods:

• Synthesis of a novel spiro analogue by substituting the piperidine ring of fentanyl with 2-azaspiro[3.3]-heptane.
• In vitro receptor binding assays to determine affinity for MOR, KOR, and DOR.
• In vitro assays to assess β-arrestin-2 recruitment.
• In vivo antinociception studies using hot-plate and tail-flick tests in mice.
• Pharmacokinetic studies measuring serum half-life after intravenous administration in mice.
• In vivo respiratory function assessment using whole-body plethysmography in mice.

Main Results:

• The spiro analogue exhibited MOR-preferred binding (MOR > KOR ≫ DOR) and did not recruit β-arrestin-2.
• Full antinociception was observed in hot-plate and tail-flick tests, albeit with a ~100-fold lower potency compared to fentanyl.
• The compound demonstrated favorable pharmacokinetics with a serum half-life of approximately 27 minutes in mice.
• Dose-dependent respiratory depression was observed, but only at high doses, indicating a wider therapeutic window.

Conclusions:

• Replacing the piperidine moiety with 2-azaspiro[3.3]-heptane preserves fentanyl-class antinociceptive activity while reducing respiratory liability.
• This structural modification decouples analgesic potency from respiratory depression, mapping important boundary conditions of the opioid pharmacophore.
• The spiro analogue represents a promising lead for developing next-generation opioid analgesics with an improved safety profile.